The pitch sounds almost too convenient: What if the electronic health record you already use could do most of your clinical busywork for you?
That's the bet Avo is making. The New York-based startup closed a $10 million Series A on March 31, 2026, led by Noro-Moseley Partners, with returning backers AlleyCorp, Las Olas Venture Capital, MedMountain Ventures, and Epsilon Health joining alongside newcomer Scrub Capital. The round brings Avo's total disclosed funding to roughly $18 million since its 2020 founding—a modest sum in an increasingly noisy field of clinical AI companies promising to ease physician burnout.
What sets Avo apart, at least according to its founders, isn't another transcription bot or ambient listening device. It's the platform play: integrating AI directly into existing EHR workflows, layering in trusted clinical guidelines, and writing results back into the medical record without forcing clinicians to toggle between yet another application.
Whether that approach wins over hospital buyers—or gets crushed by EHR giants building similar features in-house—is the $18 million question.
Why Investors Are Paying Attention
Noro-Moseley's lead check signals something investors have been whispering about for the past year: themarket may be done with point solutions. Health systems are already drowning in software vendors. The appeal of a platform that consolidates pre-charting, ambient documentation, clinical decision support, and care coordination into one integrated layer is obvious. Whether it's technically feasible at scale is another matter.
Avo isn't disclosing its valuation, which is telling in its own way. The company previously raised $5 million in a June 2023 seed round led by AlleyCorp, following an earlier $3 million round in mid-2021. In the current climate—where AI health startups are either skyrocketing or stalling—staying quiet on valuation suggests pragmatism, or perhaps just caution.
The capital will fund platform development and expansion across hospital systems and ambulatory networks, Avo says. Translation: sales cycles are long, contracts are complex, and the company needs runway to prove it can land enterprise customers beyond early adopters.
The Numbers Hospitals Care About
Avo's customer metrics read like a health system CFO's wish list—assuming they hold up under scrutiny.
According to the company's March 31, 2026 announcement, one large inpatient hospital cut clinical documentation time by 35%. A multinational ambulatory organization saved $11.6 million annually. A large academic medical center captured an additional $7.5 million in annual reimbursement through better documentation integrity. A primary care network increased completed outpatient encounters by 28%. A national urgent care chain improved dosing quality compliance by 35%.
These figures are company-reported, not independently verified. And in the world of health IT vendor claims, skepticism is warranted. But the breadth of impact areas—efficiency, revenue capture, quality metrics—suggests Avo is targeting the pain points that actually move purchasing decisions.
The platform includes Chart Assist for pre-charting and rounding, Ask Avo for AI-powered clinical consultation within the EHR, AI Scribe for ambient documentation, and AI Pathways for care coordination. It's an ambitious product suite for a company with between 11 and 50 employees, according to LinkedIn data from early 2026.
Deep in the EHR Weeds
Here's where Avo gets technical—and where it might have a genuine moat, at least for now.
The company has built integrations with Epic (including Care Everywhere data reads and note write-back), MEDITECH Expanse, athenahealth, and Juno Health. In August 2025, Avo joined MEDITECH's Alliance partnership program, listing early customers including Berkshire Health Systems, Ozarks Healthcare, Moab Regional Hospital, Deborah Heart & Lung Center, and Pella Regional Health Center.
A January 2026 partnership with Acmeware enabled real-time FHIR data integration for MEDITECH customers—early adopters include Emanate Health, Holyoke Medical Center, and Moab Regional Hospital. The athenahealth Marketplace listing launched in April 2025, followed by a December 2025 tie-up with Marathon Health, a national advanced primary care provider.
Neighbor Health, Massachusetts' largest federally qualified health center, published a case study in March 2026 showing that 73% of clinicians caught missed information or care gaps using Avo's Pre-Charting Assist within Epic. Seventy-eight percent reported improved efficiency. Again, customer-reported metrics, but they're specific enough to be credible.
The Knowledge-Base Bet
Concurrent with the Series A, Avo announced a partnership with EBSCO Clinical Decisions to embed DynaMed content into its Ask Avo tool. The move creates what Avo describes as the first context-aware AI consult tool, surfacing evidence-based recommendations grounded in both the patient's EHR data and DynaMed's clinical guidelines.
It's a clever differentiation strategy. While competitors like Nuance's DAX Copilot (embedded in Epic at major systems including Northwestern Medicine) and Abridge (which rolled out real-time prior authorization capabilities in January 2026) focus primarily on transcription and administrative automation, Avo is attempting to layer clinical decision support directly into the workflow.
The company already partnered with MCG Health in September 2025 to launch "Discharge Assist Informed by MCG," an AI tool designed to reduce hospital length of stay. Pilot sites include Englewood Health and Ozarks Healthcare. Avo also works with KDIGO to digitize chronic kidney disease guidelines at the point of care, a partnership dating back to 2022.
Whether bundling knowledge bases actually improves clinical outcomes—or just adds complexity—is a question health IT observers continue to debate. But it positions Avo as more than a dictation tool.
A Crowded, Fast-Moving Field
The clinical AI copilot market is both booming and consolidating. Suki integrated ambient documentation with MEDITECH Expanse last July. Navina raised a $55 million Series C in March 2025 for its AI copilot focused on value-based primary care. Innovaccer has launched care management copilots with EHR write-back.
Physician adoption is accelerating. A February 2025 AMA survey found that 66% of physicians were using health AI in 2024, up 78% from the prior year. Bessemer Venture Partners' State of Health AI 2026 report, published in January, noted that the majority of health tech funding is now flowing to AI companies, with particular interest in pre-visit risk stratification, real-time monitoring, and revenue cycle optimization.
In other words: everyone sees the opportunity. Not everyone will survive.
Who's Building This
Avo's founding team includes Dr. Yair Saperstein, the CEO, who brings an internal medicine background and Epic implementation experience from Mount Sinai. Dr. Joongheum "PJ" Park, chief product and AI officer, is an internal medicine physician who taught himself AI engineering. Laurence Coman, the COO, hails from Columbia Business School. It's a small team with deep clinical roots—an asset in a market where physician trust is everything.
Founded in 2020 and still based in New York, Avo now has the capital to move beyond early adopters and chase enterprise hospital contracts. Those sales cycles are long, often six to twelve months or more, but the contract values can be substantial.
The Platform Gamble
Avo is betting that health systems will consolidate around platforms delivering multiple AI workflows rather than managing a patchwork of single-purpose tools. It's a reasonable thesis. Hospital IT departments are exhausted by vendor sprawl.
But the risk is real. EHR vendors themselves—Epic, Oracle Health (formerly Cerner), MEDITECH—are building native AI capabilities. If they execute well, independent platforms like Avo could find themselves squeezed out, relegated to niche use cases or acquisition targets.
For now, Avo has runway, a product roadmap anchored in real clinical workflows, and a growing list of health system customers willing to pilot its tools. Whether the platform approach wins out over specialized point solutions—or gets absorbed by the EHR giants—will likely be clear within the next eighteen months.
The company declined to comment on M&A interest. But in this market, that's usually just a matter of time.
